Merck cholesterol drug cuts heart risk by 9 pct in study

Aug 29 (Reuters) – A large study of Merck & Co Inc’sexperimental cholesterol drug anacetrapib found that it cut therisk of heart attack and death by a modest 9 percent, whichcould be due to its affect on bad LDL cholesterol, researcherssaid on Tuesday.
The post Merck cholesterol drug cuts heart risk by 9 pct in study appeared first on RocketNews | Top News Stories From Around the Globe.